Study to Evaluate the Safety and Efficacy of Alefacept (Amevive) in Subjects With Moderate to Severe Atopic Dermatitis

Phase 4 Completed 5 enrolled Rush University Medical Center Astellas Pharma US, Inc. · collab

NaSingle-groupOpen-labelTreatment

Summary

This study will assess the safety, tolerability, and efficacy of Alefacept in patient with moderate to severe atopic dermatitis who could not be adequately controlled with topical therapies.

Timeline

Start: 2008-01
Primary completion: 2009-09
Completion: 2009-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Alefacept	Protein / enzyme biologic	15 mg	Intramuscular

Study to Evaluate the Safety and Efficacy of Alefacept (Amevive) in Subjects With Moderate to Severe Atopic Dermatitis

Summary

Timeline

Drugs

Indications